Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.73 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.73 |
| ▸ | MEN1 | O00255 | 1/20 | 0.73 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.69 |
| ▸ | HPGD | P15428 | 1/20 | 0.69 |
| ▸ | POLB | P06746 | 2/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9356614 | 0.86 | MAPT (0.76) | MAPTALDH1A1KMT2AMEN1SMN1; SMN2 | |
| Trimetozine SCHEMBL114786 | 0.84 | MAPT (0.72) | MAPTALDH1A1KMT2AHPGDPOLB | |
| SCHEMBL9174229 | 0.82 | ALDH1A1 (1.00) | MAPTALDH1A1KMT2ASMN1; SMN2HPGD | |
| SCHEMBL29596492 | 0.82 | MAPT (0.68) | MAPTALDH1A1KMT2APOLB | |
| SCHEMBL9356116 | 0.81 | MAPT (0.68) | MAPTALDH1A1KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL9356002 | 0.81 | MAPT (0.69) | MAPTALDH1A1KMT2ASMN1; SMN2HPGD | |
| SCHEMBL8937386 | 0.80 | ALDH1A1 (0.73) | MAPTALDH1A1KMT2AMEN1SMN1; SMN2 | |
| Vanitiolide SCHEMBL1643547 | 0.80 | ALDH1A1 (1.00) | MAPTALDH1A1KMT2ASMN1; SMN2HPGD | |
| SCHEMBL9585600 | 0.77 | MAPT (0.61) | MAPTALDH1A1KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL17131881 | 0.77 | MAPT (0.61) | MAPTALDH1A1KMT2AMEN1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 200 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101066245-A | Orally taken emulsion and its prepn | ZHU FANGHAI (CN) | 2007-11-07 | — | — | CN | claimed |
| EP-1336602-A1 | Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases | Scaramuzzino, Giovanni (IT) | 2003-08-20 | — | — | EP | claimed |
| CN-1294519-A | Pharmaceutical composition containing a compound having an activity of promoting the absorption of an active ingredient | INPHARMA SA (CH) | 2001-05-09 | — | — | CN | claimed |
| EP-1073470-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2001-02-07 | — | — | EP | claimed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | claimed |
| US-5221673-A | Mixing alkyloxyphenyl-thioxomethylmorpholine derivatives with inert solid or liquid carriers or diluent in animal feed for weight-gain | EGIS GYOGYSZERGYAR (HU) | 1993-06-22 | — | — | US | claimed |
| EP-0492483-A2 | Compositions containing 1 or more N-[phenyl-(thioxomethyl)]-morpholine derivative(s) and the use of these compounds | EGIS GYOGYSZERGYAR (HU) | 1992-07-01 | — | — | EP | claimed |
| EP-3356440-B1 | HYDROPHOBIC HIGHLY BRANCHED CARBOHYDRATE POLYMERS | PURDUE RESEARCH FOUNDATION (US) | 2024-06-05 | — | — | EP | disclosed |
| US-20240074995-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FIRST WAVE BIO, INC. | 2024-03-07 | — | — | US | disclosed |
| US-11793777-B2 | Methods and compositions for treating conditions associated with an abnormal inflammatory response | FIRST WAVE BIO, INC. (US) | 2023-10-24 | — | — | US | disclosed |
| US-11744812-B2 | Methods of treatment | FIRST WAVE BIO, INC. (US) | 2023-09-05 | — | — | US | disclosed |
| WO-2023118074-A1 | COMPRESSIBLE AND FREE FLOWING CO-PROCESSED MESOPOROUS SILICA | UNIVERZA V LJUBLJANI (SI) | 2023-06-29 | — | — | WO | disclosed |
| US-20230201143-A1 | METHODS OF TREATMENT | FIRST WAVE BIO, INC. | 2023-06-29 | — | — | US | disclosed |
| US-5254547-A | Thioacid amide derivatives and fodder compositions containing the same | EGIS GYOGYSZERGYAR (HU) | 1993-10-19 | — | — | US | disclosed |
| US-5234934-A | Derivatives of a 1-(2-hydroxy-3-N-hetpropoxyimino)-2-phenyl methylene)cycloalkane; antiarrhymia,-secretory and -inflammatory agents; tranquilizers; local anaesthetics | EGIS GYOGYSZERGYAR (HU) | 1993-08-10 | — | — | US | disclosed |
| US-5221673-A | Mixing alkyloxyphenyl-thioxomethylmorpholine derivatives with inert solid or liquid carriers or diluent in animal feed for weight-gain | EGIS GYOGYSZERGYAR (HU) | 1993-06-22 | — | — | US | disclosed |
| CN-1064276-A | 1,2,4-triazolo [1,5-a] pyrimidine derivatives and preparation method thereof | EGYT GYOGYSZERVEGYESZETI GYAR (HU) | 1992-09-09 | — | — | CN | disclosed |
| US-5130487-A | Cardiovascular disorders, tranquilizers for central nervous systems or for digestive system problems | EGIS GYOGYSZERGYAR (HU) | 1992-07-14 | — | — | US | disclosed |
| EP-0492484-A1 | Substituted N-[phenyl-(thioxomethyl)]-morpholine derivatives, a process for preparing them as well as compositions containing these compounds and the use of them | EGIS GYOGYSZERGYAR (HU) | 1992-07-01 | — | — | EP | disclosed |
| EP-0492483-A2 | Compositions containing 1 or more N-[phenyl-(thioxomethyl)]-morpholine derivative(s) and the use of these compounds | EGIS GYOGYSZERGYAR (HU) | 1992-07-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240074995-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FH, CS, ECHS1 | MAPT 954/4885ALDH1A1 2174/4885KMT2A 3595/4885 |
| US-11744812-B2 | Methods of treatment | ACE2, ACE, SI | MAPT 845/4885ALDH1A1 3977/4885KMT2A 2952/4885 |
| US-20230201143-A1 | METHODS OF TREATMENT | ACE2, ACE, SI | MAPT 753/4885ALDH1A1 3889/4885KMT2A 2890/4885 |
| US-11793777-B2 | Methods and compositions for treating conditions associated with an abnormal inflammatory response | FH, CS, ECHS1 | MAPT 971/4885ALDH1A1 2230/4885KMT2A 3704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.